Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 9 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (2)
P 1 (2)
P 2 (1)

Trial Status

Recruiting4
Active Not Recruiting2
Unknown2
Not Yet Recruiting1

Clinical Trials (9)

Showing 9 of 9 trials
NCT06710548Not ApplicableRecruiting

REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

NCT07359066Phase 1Recruiting

An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

NCT07303218Active Not Recruiting

The HER Project: HRD in EGFR-mutated NSCLC

NCT03212742Phase 1Active Not Recruiting

Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients

NCT05538091Phase 2Recruiting

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT06838429Not Yet Recruiting

PARPi and Ovarian Cancer Survival

NCT06197581Not ApplicableRecruiting

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

NCT05044091Unknown

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

NCT04582552Unknown

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Showing all 9 trials

Research Network

Activity Timeline